Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle(The University of Texas MD Anderson Cancer Center), Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Ivan Borbath, Wei Peng Yong(National University of Singapore), Philip A. Philip(Wayne State University), Anthony B. El-Khoueiry(USC Norris Comprehensive Cancer Center), Mitesh J. Borad(Jacksonville College), Robin Kate Kelley(UCSF Helen Diller Family Comprehensive Cancer Center), Li Ai(Kunming Medical University), Harris S. Soifer(Kura Oncology (United States)), S. Tanasanvimon(Chulalongkorn University), Stacie Peacock Shepherd(QED Technologies (United States)), Lipika Goyal(Stanford Medicine), Tanios Bekaii‐Saab(WinnMed), Susan Moran(QED Technologies (United States)), Teresa Macarulla(Vall d'Hebron Hospital Universitari), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Sameek Roychowdhury(The Ohio State University Wexner Medical Center), Amit Pande(QED Technologies (United States)), Saeed Sadeghi(University of California, Los Angeles), Michael Bitzer(University Children's Hospital Tübingen), Dirk‐Thomas Waldschmidt(University of Cologne), Karl Heinz Weiss(Heidelberg University)
Cited by 423
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
Landscape of Microsatellite Instability Across 39 Cancer Types
|JCO Precision Oncology|2017|1.5k